Use of sodium-glucose cotransporter-2 inhibitor (SGLT2) drugs should continue in patients with diabetes, in line with current recommendations, conclude the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE), in response to recent concerns from regu...
Qtern, developed by AstraZeneca, combined DPP4 inhibitor saxagliptin (brand name: Onglyza) with SGLT2 inhibitor dapagliflozin (brand name: Forxiga). Ildong and AstraZeneca said the one tablet of the combo drug once daily could generate the effect of the two different types of drugs. If patients...